ArticleTranslational lung cancer research2021

Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer.

Youli Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.